CTL019: latest news - GoINPHARMA
Friday, 16 November 2018 - 19:19


EMA: Novartis submits MAA for CAR-T therapy Kymriah

Novartis announced today that that it has submitted a MAA (Marketing Authorization Application) to EMA for CTL019 (tisagenlecleucel) for two different indications. Indeed, the application refers both to the treatment of children and young adults with B-cell ALL (acute lymphoblastic…